Abilia, a leading provider of assistive technology, today announced the acquisition of LivAssured and their advanced epilepsy alarm system NightWatch. Bringing a clinically validated, MDR-Class II certified solution into the assistive technology portfolio, this strategic acquisition enhances Abilia’s offering with an even stronger portfolio to support individuals living with epilepsy, as well as those who care for them — whether at home, in hospitals, or in community settings.
NightWatch seizure detection technology is invented and developed by LivAssured in collaboration with a consortium of Dutch neurologists, patient organizations, universities, and technology companies; founded on the groundbreaking research by Kempenheaghe, University Hospital of Utrecht, and Dutch epilepsy centre SEIN. With a strong track record of growth and a well-established presence across Europe, LivAssured is recognized for its commitment to improving safety and quality of life for individuals with epilepsy anchored in robust and extensive clinical evidence.
“By bringing NightWatch, a user-centred and clinically validated solution, into our portfolio we are better positioned than ever to support those living with epilepsy, and the families and professionals who care for them,” says Tove Christiansson, CEO of Abilia and Head of Business Area Assistive Tech at MedCap. "We are very delighted to welcome the team and together be able to support even more people with a product that is trusted and appreciated.”
The acquisition aligns with Abilia’s long-term strategy to broaden its impact in the assistive technology sector, particularly within epilepsy care — an area where timely detection and response are critical. Together, the combined expertise and capabilities of both companies will accelerate innovation and improve outcomes for more users across the care spectrum.
“We are proud of what we have achieved with NightWatch together with our partners and the epilepsy community over the past years,” said Jeroen van den Hout, CEO of LivAssured. “By joining Abilia, we can take the next step in our mission and bring NightWatch to even more families worldwide.”
About LivAssured and NightWatch
LivAssured’s product NightWatch is a medical device that detects epileptic seizures and has been developed for more than 10 years with significant commercial progress achieved in Europe in recent years. The company currently has a turnover of approx. 4 MEUR and 15 employees, and an ambitious growth plan. The acquisition complements the offering of Abilia and the Business Area Assistive Tech.
The seizure detection technology in NightWatch has been invented and developed in collaboration with a consortium of Dutch neurologists, patient organizations, universities, and technology companies.
NightWatch+ includes a comfortable, wireless sensor that continuously monitors to detect seizures using heart rate and movements while the wearer sleeps. NightWatch+ is intended to be used at home or residential care facilities by people diagnosed with epilepsy aged 4 years and older, having nocturnal epileptic motor seizures and caregivers thereof. When NightWatch+ detects a potentially dangerous seizure, a warning is transmitted via a wireless signal from the sensor to the corresponding alarm station to notify a caregiver.
Read more: www.nightwatchepilepsy.com
